Esperion Therape Stock Price, News & Analysis

Esperion (NASDAQ: ESPR) will present at the Jefferies Global Healthcare Conference – London on November 18, 2025 at 8:00 a.m. GMT (3:00 a.m. ET).

The presentation will be webcast live and accessible via the company investor website. A replay will be available approximately two hours after the call and will be archived on the company website for approximately 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C and is advancing next-generation ACLY inhibitor programs supported by prior CLEAR outcomes research.

Esperion (NASDAQ: ESPR) will host a virtual Key Opinion Leader event on Tuesday, November 11, 2025 at 2:00 p.m. ET to discuss clinical and real-world challenges of statin intolerance and impacts on patient outcomes. The event is led by LeAnne Bloedon, VP, Head of Clinical Development, and features experts including Fatima Rodriguez, MD, MPH, and Dharmesh S. Patel, MD.

The company highlighted that nearly 20% of patients discontinue statins within one year and emphasized dialogue on strategies—including bempedoic acid therapies. A live audio webcast and replay (available ~2 hours after the call) will be posted on the investor section of the Esperion website and archived for ~90 days.

Esperion (NASDAQ: ESPR) announced that two analyses from the CLEAR Outcomes trial were accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, November 7-10, 2025.

An oral presentation titled “Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial” is scheduled for November 9, 2025, 9:45–11:00 AM CST, presented by Carolina Pires Zingano, MD of Cleveland Clinic. A poster, “Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial”, will appear in the moderated digital poster session VM.MDP.07 on November 9, 2025, 11:50 AM–1:05 PM CST, presented by Bernardo Frison Spiazzi, MD of Cleveland Clinic.

Company leadership highlighted that CLEAR Outcomes continues to yield clinically relevant insights on statin intolerance and treatment options for patients with elevated LDL-C.

Esperion (NASDAQ: ESPR) will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.

Management will host a live webcast at 8:00 a.m. ET to discuss results and business updates; a replay will be available about two hours after the call and archived on the company website for ~90 days.

Esperion is a commercial-stage biopharmaceutical company marketing the only FDA-approved oral, once-daily non-statin therapies for patients with elevated LDL-C, supported by the ~14,000-patient CLEAR cardiovascular outcomes trial. The company is advancing next-generation ATP citrate lyase inhibitor (ACLYi) programs and pursuing international partnerships and commercial expansion.

Esperion (NASDAQ: ESPR) nominated ESP-2001, a highly-specific allosteric ACLY inhibitor, as its preclinical development candidate for primary sclerosing cholangitis (PSC) on October 16, 2025. The company will begin IND-enabling studies with a goal to file an IND with the FDA in 2026 to start first-in-human trials. Preclinical models reportedly showed consistent reductions in markers of liver and bile duct injury, inflammation, and fibrosis. Esperion retains exclusive global development and commercialization rights and cites an estimated diagnosed PSC prevalence of ~76,000 in the U.S. and Europe and a potential market opportunity of over $1 billion annually. ESP-2001 may be eligible for Orphan Drug, Fast Track, and PRIME designations.

Esperion (Nasdaq: ESPR) priced an underwritten public offering of 30,000,000 common shares at $2.50 per share, with a 30-day underwriter option for up to 4,500,000 additional shares. Gross proceeds before fees are expected to be approximately $75.0 million, excluding any exercise of the option.

The offering is expected to close on or about October 9, 2025, subject to customary closing conditions, and is being sold pursuant to an effective shelf registration declared effective by the SEC on April 29, 2025. Piper Sandler and Cantor Fitzgerald are joint book‑running managers.

Esperion (Nasdaq: ESPR) announced on October 7, 2025 that it has commenced an underwritten public offering of its common stock, with all shares to be sold by the company.

The offering includes a 30‑day option for underwriters to buy up to an additional 15% of the shares. The offering is being made from an effective shelf registration declared effective by the SEC on April 29, 2025 (File No. 333-286631). Piper Sandler and Cantor Fitzgerald are joint book‑running managers.

Completion, size and terms are subject to market and other conditions; a preliminary prospectus supplement will be filed with the SEC and posted at www.sec.gov.

Esperion (NASDAQ: ESPR) announced a settlement with Dr. Reddy’s Laboratories resolving ANDA litigation over NEXLETOL and NEXLIZET. Under the agreement, Dr. Reddy’s will not market generic versions in the U.S. before April 19, 2040, except for customary limited exceptions. Esperion previously settled with Micro Labs, Hetero and Accord earlier in 2025. Esperion’s U.S. Patent No. 7,335,799 (bempedoic acid) expires December 2030; with this settlement there are no remaining challenges to that patent’s validity or infringement in the pending litigation. Other Esperion patents at issue expire March 2036 and June 2040. Litigation continues against several other ANDA filers, and there is no assurance those cases won’t permit earlier generic entry.

Esperion (NASDAQ: ESPR) announced that its partner Otsuka Pharmaceutical has received approval from Japanese regulators to market NEXLETOL for treating hypercholesterolemia and familial hypercholesterolemia in Japan. This approval marks NEXLETOL's entry into the third-largest global market for cardiovascular prevention.

The approval triggers milestone payments to Esperion under their partnership agreement with Otsuka, which includes tiered royalties of 15-30% on net sales in Japan and additional sales milestone payments. NEXLETOL, a non-statin LDL-C lowering therapy, is now approved across the U.S., Europe, and Japan, establishing a strong global presence for Esperion's cholesterol treatment.